Trust Homepage > Pathology Homepage

Test and Tubes Database
ID:776 Serum Free Light Chain
Search Links: General Info : Protocols : Patient Info

DescriptionThis test detects the present of serum immunoglobulin kappa and lambda free light chains, and expresses these as a ratio, the sFLC ratio.
IndicationsFLC should not be used as a screen for Multiple Myeloma. For use as an adjunct to serum and urine electrophoresis and immunofixation as a diagnostic marker for Multiple Myeloma and other plasma cell dyscrasias.
Additional InfoNot routinely available. Available to Haematologists only.
Concurrent Testsna
Dietary Requirementsna

InterpretationMeasurement of the kappa:lambda ratio provides a numerical indicator of clonality (Tumours produce monoclonal excess of only one of the light chain types, often with bone marrow suppression of the alternative light chain, so that the kappa:lambda ratios becomes skewed). A patient with a 'kappa' paraprotein (eg IgG Kappa, Kappa LCMM) will have an increased serum free ligh chain kappa:lambda ratio. A patient with a 'lambda' paraprotein with have a decreased serum free light chain kappa:lambda ratio.

Ref. Range (Male)
Ref. Range (Female)
Ref. Range (Paed)
Ref. Range NotesAs set by Siemens N latext sFLC assay: Free kappa: 6.7-22.4 Free Lambda: 8.3-27 Kappa:Lambda Ratio: 0.31 - 1.56 (The sFLC kappa:lambda ratio in patients with renal failure do not differ from the reference limits for healthy controls)
Unitsmg/L


IP Acute TAT- Contact Laboratory
IP Routine TAT14 days
GP Acute TAT- Contact Laboratory
GP Routine TAT14 days
Turnround CommentNA
Originally edited by : Anna McHugh. Last edited on 14/09/2018 14:33:40. Published By BD on 14/09/2017 14:33:40.